No Data
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
Maxim Group analyst Jason McCarthy maintains $Scynexis(SCYX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 26.4% and a
Promising Clinical and Financial Prospects for SCYNEXIS: A Comprehensive Buy Rating Analysis
Express News | Scynexis Inc - Cash Runway Exceeds Two Years
Express News | Scynexis : GSK Will Also Pay Mid-Single Digit to Mid-Teen Digit Tiered Royalties on Totality of Ibrexafungerp Sales Across All Indications
Express News | Scynexis Inc - Milestone Payment Triggered by Clinical Study Reports
Express News | Scynexis : Eligible for Additional $323 Million in Milestone Payments
No Data